secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxart, Inc. (VXRT)
CIK:        0000072444
Form:       8-K
Filed at:   2025-02-10T23:59:59+00:00
Accession:  0001437749-25-003319
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxart secures $105.9M BARDA funding increase; Phase 2b trial to test KP.2 vaccine vs mRNA
--------------------------------------------------------------------------------

- Total BARDA funding for the Phase 2b trial now $240.1M, up from $134.2M.
- Next trial portion will enroll 10,000 participants comparing Vaxart's KP.2 oral vaccine against an mRNA KP.2 comparator.
- Sentinel cohort of 400 (XBB vs mRNA XBB) completed; DSMB recommended proceed without modification.
- Vaxart awaiting BARDA approval to commence dosing in the KP.2 portion.
- Funding increase supports manufacturing of new KP.2 lots and expanded clinical activities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/72444/000143774925003319/0001437749-25-003319-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/72444/000143774925003319/vxrt20250210_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-003319

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer